Table 2.
Main clinical outcomes of the project at 4 weeks after treatment change
| Twice weekly HD | Thrice weekly HD | P value | |
|---|---|---|---|
| URR (%)a | 72.6 [66.4–77.2] | 69.7 [62.7–74.8] | 0.009 |
| Corrected Calciumb (mmol/L) | 2.33 [2.20–2.42] | 2.33 [2.22–2.43] | 0.921 |
| Phosphatec (mmol/L) | 1.77 [1.44] | 1.65 [1.33–2.09] | 0.117 |
| Potassiumd (mmol/L) | 4.80 [4.30–5.40] | 4.90 [4.40–5.40] | 0.329 |
| UF per session (L) | 1.50 [1.00–2.03] | 2.00 [1.40–2.63] | < 0.001 |
| COVID-19 positive (%) | 9 (5.4) | 20 (8.5) | 0.245 |
| Hospitalisations (%) | 13 (7.8) | 17 (7.2) | 0.813 |
| Deaths (%) | 6 (3.6) | 6 (2.5) | 0.535 |
Results are expressed as median [IQR; interquartile range] or n (%). p-value calculated using Mann-Whitney U Test. Categorical variables were analysed by Chi-square test. Hospitalisation data includes patients who were hospitalised for COVID-19 and prior to death. amissing for 56 patients in twice weekly group and 126 patients in thrice weekly group. bmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. cmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. dmissing for 32 patients in thrice weekly group
COVID-19, hospitalisations and deaths % calculated in relation to original number of patients n = 166 / n = 236. Abbreviations: URR Urea reduction ratio, UF Ultrafiltration